Medical Condition News

RSS

Amgen announces results from three studies on the safety and efficacy of Nplate

Amgen Inc. today announced results from three studies on the safety and efficacy of Nplate® (romiplostim) in adult patients with myelodysplastic syndromes (MDS).

7 Dec 2009

Vitamin D supplements may aid in treating cancer

The findings support the growing association between vitamin D and cancer risk and outcomes, and suggest that vitamin D supplements might help even those patients already diagnosed with some forms of cancer, says Dr. Drake.

7 Dec 2009

Updated safety data from Phase 2b 003-A1 study of carfilzomib announced

Onyx Pharmaceuticals, Inc. today announced updated safety data from the pivotal Phase 2b 003-A1 study, known as the 003 trial, demonstrating that carfilzomib is well-tolerated in heavily pre-treated relapsed and refractory multiple myeloma patients.

7 Dec 2009

Study finds substantial variation in hydroxyurea utilization for sickle cell disease

A new study by researchers from the Medical College of Wisconsin, in Milwaukee, found a substantial variation in hydroxyurea utilization for pain and other sickle cell disease complications in children.

7 Dec 2009

New findings may yield more effective therapies for infants with blood cancer

Pediatric oncologists have identified specific genes, dubbed partner genes, that fuse with another gene to drive an often-fatal form of leukemia in infants. By more accurately defining specific partner genes, researchers expect to better predict which infants may benefit from particular treatments.

7 Dec 2009

ImmunoGen reports encouraging clinical data of IMGN901

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, today reported encouraging clinical data with its IMGN901 product candidate in the treatment of relapsed and relapsed/refractory multiple myeloma (MM), including prolonged benefit in patients whose disease had progressed on multiple prior treatment regimens.

6 Dec 2009

FDA approves new technology tool for breast cancer screening

The FDA has approved new technology that now allows radiologists to detect breast cancer sooner and faster. The SonoCine Automated Whole-breast Ultrasound Method and is being offered by only one facility in Arizona - Arizona Breastnet, in Scottsdale.

6 Dec 2009

Stem cell treatment: A new hope for Multiple Sclerosis

RNL Bio Co., Ltd, (www.rnl.co.kr) a leading biopharmaceutical company specialized in adult stem cell therapeutics announced today that a 46-year-old female, Kang Sook Park's Multiple Sclerosis improved tremendously after receiving stem cell treatment. Park was suffering from MS (Multiple Sclerosis), an autoimmune disease that affects the central nervous system (brain and spinal cord).

6 Dec 2009

Dabigatran etexilate offers effective therapy to prevent recurrent VTE

Results from the landmark RE-COVER(TM) study were presented today at the American Society of Hematology Annual Meeting and published online in the New England Journal of Medicine.

6 Dec 2009

New study reveals genetic alteration can lead to severe childhood obesity

Scientists in Cambridge have discovered that the loss of a key segment of DNA can lead to severe childhood obesity. This is the first study to show that this kind of genetic alteration can cause obesity. The results are published today in Nature.

6 Dec 2009

Bortezomib can improve control of GVHD and immune system recovery

A drug that has become a mainstay of multiple myeloma treatment may outperform alternative therapies in re-establishing the immune system of patients who have received stem cell transplants from unrelated, partially matched donors, according to early clinical trial results to be presented by Dana-Farber Cancer Institute investigators at the American Society of Hematology's (ASH) annual meeting on Sunday, Dec. 6 (Abstract 48, Ernest N. Morial Convention Center, Room 243-245, 5:45 pm CT).

6 Dec 2009

New treatment options for leukemia and myeloproliferative disorders introduced

Leukemia and myeloproliferative disorders are serious and often deadly blood cancers. Research presented today at the 51st Annual Meeting of the American Society of Hematology introduces potential new treatment options and improved diagnostic methods for patients suffering from acute promyelocytic leukemia, chronic myeloid leukemia, infant acute lymphoblastic leukemia, and myelofibrosis that are based on a better understanding of the underlying genetic causes of these conditions.

6 Dec 2009

Lab grown muscle cells raise hope for gastric reflux and fecal incontinence

A new study shows that muscle cells grown in the lab can restore an intestine's ability to squeeze shut properly. The work, performed in dogs and rats, might ultimately help treat patients with conditions such as gastric reflux and fecal incontinence.

5 Dec 2009

New Emergency Stroke System ensures patients’ access to effective treatment

Thanks to Los Angeles County's new Emergency Stroke System, individuals who experience a stroke may now be able to more quickly access some of the latest advances in stroke interventions.

5 Dec 2009

Bayer Diabetes Care announces the winners of 'Express Your Simple Win Creativity Contest'

Bayer Diabetes Care today announced the three grand prize winners of Bayer's "Express Your Simple Win Creativity Contest." Nick Jonas, of the Jonas Brothers, selected the winning video entries submitted by children with diabetes from across the country.

5 Dec 2009

Critical enzyme activity provides new insight into heart disease mechanisms

Using a new mathematical model of heart cells, University of Iowa investigators have shown how activation of a critical enzyme, calmodulin kinase II (CaM kinase), disrupts the electrical activity of heart cells.

5 Dec 2009

Oxygen Biotherapeutics commences enrollment in clinical trial of Oxycyte emulsion for TBI

Oxygen Biotherapeutics, Inc. today announced that the first patient has been enrolled in the company's Phase II-b, dose escalation, clinical trial in Switzerland for use of Oxycyte(TM) emulsion in traumatic brain injury (TBI). Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.

5 Dec 2009

AES: Progress in epilepsy management not reached millions of people around the world

Substantial progress has been made over the last 15 years in the healthcare community's ability to diagnose and treat epilepsy and its complications. Yet this progress in epilepsy management has not reached most of the 50 million people around the world, including many of the nearly three million people in the United States who have the disorder.

5 Dec 2009

Licensing agreement to develop and commercialize potential treatment for Gaucher’s disease signed

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. represented Protalix (NYSE-Amex: PLX), a leading biopharmaceutical company, in its licensing agreement with Pfizer Inc. to develop and commercialize a potential treatment for Gaucher’s disease, a genetic disorder.

5 Dec 2009

Patients new to chronic disease medication face risk of medication discontinuation, finds study

In a new study published online today by Clinical Therapeutics, researchers from Adheris, Inc., an inVentiv Health company, found that patients new to chronic disease medication face the greatest risk of medication discontinuation during the first 30 days of treatment—with rates of discontinuation ranging from 29.6% to 78.1%.

5 Dec 2009